Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
Sickle Cell Anemia (SCA) occurs in 300,000 newborns per year in the world, with 150,000 affected births in Nigeria, alone.
2 Nigeria sites
1 United States site
5 to 26 Years
Sickle cell disease (SCD) is the most common genetic disease, affecting about 25 million people worldwide.
1 United States site
1 Nigeria site
16 to 26 Years
This pilot research is aimed to assess the needs of patients and health workers involved in Sickle Cell Disease (SCD) management in Nigeria.
4 Nigeria sites
> 18 Years
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.
16 United States sites
5 Nigeria sites
4 Egypt sites
3 Italy sites
3 Kenya sites
3 United Kingdom sites
2 Oman sites
2 Ghana sites
2 Saudi Arabia sites
2 to 14 Years
Phase 3
Sickle cell disease is very common in Nigeria.
4 United States sites
3 Nigeria sites
6 to 60 Years
N/A
Except for children with HIV, all recommendations for treatment of childhood malnutrition are for children 5 years of age agree to participate over a 12-week period.
3 Nigeria sites
1 United States site
5 to 12 Years
Phase 2
The investigators propose to adopt sustainable community networks (in this case churches) to implement an integrated community-based screening that incorporates mobile health technology (mHealth) to make prenatal test results available at the point-of-delivery to guide medical management.
1 Nigeria site
> 18 Years
N/A
The overall goal of the proposed study is to determine the effectiveness of hydroxyurea therapy for secondary stroke prevention and prevention of other neurological events in children with SCA with an acute overt stroke.
2 Nigeria sites
1 to 16 Years
Phase 3
The vast majority of births with sickle cell disease (SCD) occur in Africa and 90% are thought to die before the age of five.
1 Nigeria site
> 18 Years
HbSS
Phase 4
